Study on male hormone blocking drugs for prostate cancer in Australia
Part of Cancer, Hormones & metabolism clinical trials.
This study looks at how certain drugs (darolutamide, enzalutamide, apalutamide, or abiraterone) that block male hormones are used to treat men with prostate cancer that has spread. It aims to understand real-world treatment patterns in Australia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a male with prostate cancer that has spread to other parts of the body (metastatic hormone-sensitive prostate cancer).
- You have started taking one of these drugs for the first time: darolutamide, enzalutamide, apalutamide, or abiraterone.
- You are at least 18 years old when you first start the drug.
- You have medical records for at least 12 months before starting the drug and at least 3 months after starting.
- You have not taken any of these drugs before for your prostate cancer.
- Your prostate cancer has not become resistant to hormone therapy (castration-resistant) before or at the time you start the drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well darolutamide and similar drugs work for men whose prostate cancer has just spread to other parts of the body. It aims to understand real-world outcomes in urology clinics.
This study tests different ways of giving hormone therapy to find the right dose for men with prostate cancer that has spread. It aims to help manage the disease while limiting side effects.
This trial tests a combination of precise radiation therapy (SBRT) and a drug called darolutamide for men whose prostate cancer has spread to a limited number of other parts of the body. The goal is to see if this approach can control the cancer effectively with fewer side effects.
This study looks at how well men with prostate cancer that has spread and is still hormone-sensitive stick to taking the drug apalutamide. It aims to understand real-world use and quality of life.
This study tests two different combinations of drugs for men with prostate cancer that has spread to other parts of the body but still responds to hormone therapy. It compares a new pill (tulmimetostat) combined with standard treatments like darolutamide or abiraterone to see if it can help control the cancer longer.
This trial tests whether a combination of three new drugs (SHR3680, HS-20093, and SHR2554) can help slow or stop prostate cancer growth. It is for men who are already on hormone therapy and whose PSA level is still rising.
Hear when a new Metastatic Hormonesensitive Prostate Cancer (mHSPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.